Denali Therapeutics Inc.
DNLI
$15.15
$0.261.75%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -99.63% | 191.13% | 204.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -99.63% | 191.13% | 204.74% |
| Cost of Revenue | -8.60% | 2.91% | 0.90% | -18.38% | -2.59% |
| Gross Profit | -1,588.72% | -2,341.30% | -1,795.24% | 89.25% | 92.44% |
| SG&A Expenses | 2.02% | -1.91% | 0.49% | 6.71% | 14.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.21% | 0.43% | -0.37% | 3.00% | 19.13% |
| Operating Income | -145.30% | -202.41% | -208.35% | 45.32% | 39.96% |
| Income Before Tax | -191.13% | -243.52% | -226.86% | 62.97% | 55.46% |
| Income Tax Expenses | 126.67% | 600.00% | 600.00% | 42.86% | 42.86% |
| Earnings from Continuing Operations | -191.12% | -243.56% | -226.90% | 62.96% | 55.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -191.12% | -243.56% | -226.90% | 62.96% | 55.45% |
| EBIT | -145.30% | -202.41% | -208.35% | 45.32% | 39.96% |
| EBITDA | -163.60% | -234.12% | -242.06% | 45.00% | 43.13% |
| EPS Basic | -144.79% | -197.15% | -173.05% | 67.52% | 59.36% |
| Normalized Basic EPS | -121.42% | -204.45% | -181.30% | 57.76% | 51.70% |
| EPS Diluted | -136.56% | -185.82% | -163.77% | 66.21% | 57.93% |
| Normalized Diluted EPS | -115.11% | -193.75% | -172.40% | 56.51% | 50.29% |
| Average Basic Shares Outstanding | 19.71% | 15.04% | 12.12% | 9.01% | 9.45% |
| Average Diluted Shares Outstanding | 18.87% | 14.23% | 11.30% | 9.76% | 10.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
